Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells

William C. Reinhold, Mark A. Reimers, Alika K. Maunakea, Sohyoung Kim, Samir Lababidi, Uwe Scherf, Uma T. Shankavaram, Micah S. Ziegler, Claudia Stewart, Hosein Kouros-Mehr, Hengmi Cui, Douglas Dolginow, Dominic A. Scudiero, Yves G. Pommier, David J. Munroe, Andrew P Feinberg, John N. Weinstein

Research output: Contribution to journalArticle

Abstract

E-cadherin (E-cad) is a adhesion glycoprotein, the expression of which is often reduced in invasive or metastatic tumors. To assess E-cad's distribution among different types of cancer cells, we used bisulfitesequencing for detailed, base-by-base measurement of CpG methylation in E-cad's promoter region in the NCI-60 cell lines. The mean methylation levels of the cell lines were distributed bimodally, with values pushed toward either the high or low end of the methylation scale. The 38 epithelial cell lines showed substantially lower (28%) mean methylation levels compared with the nonepithelial cell lines (58%). The CpG site at -143 with respect to the transcriptional start was commonly methylated at intermediate levels, even in cell lines with low overall DNA methylation. We also profiled the NCI-60 cell lines using Affymetrix U133 microarrays and found E-cad expression to be correlated with E-cad methylation at highly statistically significant levels. Above a threshold of ∼ 20% to 30% mean methylation, the expression of E-cad was effectively silenced. Overall, this study provides a type of detailed analysis of methylation that can also be applied to other cancer-related genes. As has been shown in recent years, DNA methylation status can serve as a biomarker for use in choosing therapy.

Original languageEnglish (US)
Pages (from-to)391-403
Number of pages13
JournalMolecular Cancer Therapeutics
Volume6
Issue number2
DOIs
StatePublished - Feb 2007

Fingerprint

DNA Methylation
Cadherins
Methylation
Cell Line
Neoplasms
Neoplasm Genes
Genetic Promoter Regions
Glycoproteins
Biomarkers
Epithelial Cells

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Reinhold, W. C., Reimers, M. A., Maunakea, A. K., Kim, S., Lababidi, S., Scherf, U., ... Weinstein, J. N. (2007). Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. Molecular Cancer Therapeutics, 6(2), 391-403. https://doi.org/10.1158/1535-7163.MCT-06-0609

Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. / Reinhold, William C.; Reimers, Mark A.; Maunakea, Alika K.; Kim, Sohyoung; Lababidi, Samir; Scherf, Uwe; Shankavaram, Uma T.; Ziegler, Micah S.; Stewart, Claudia; Kouros-Mehr, Hosein; Cui, Hengmi; Dolginow, Douglas; Scudiero, Dominic A.; Pommier, Yves G.; Munroe, David J.; Feinberg, Andrew P; Weinstein, John N.

In: Molecular Cancer Therapeutics, Vol. 6, No. 2, 02.2007, p. 391-403.

Research output: Contribution to journalArticle

Reinhold, WC, Reimers, MA, Maunakea, AK, Kim, S, Lababidi, S, Scherf, U, Shankavaram, UT, Ziegler, MS, Stewart, C, Kouros-Mehr, H, Cui, H, Dolginow, D, Scudiero, DA, Pommier, YG, Munroe, DJ, Feinberg, AP & Weinstein, JN 2007, 'Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells', Molecular Cancer Therapeutics, vol. 6, no. 2, pp. 391-403. https://doi.org/10.1158/1535-7163.MCT-06-0609
Reinhold, William C. ; Reimers, Mark A. ; Maunakea, Alika K. ; Kim, Sohyoung ; Lababidi, Samir ; Scherf, Uwe ; Shankavaram, Uma T. ; Ziegler, Micah S. ; Stewart, Claudia ; Kouros-Mehr, Hosein ; Cui, Hengmi ; Dolginow, Douglas ; Scudiero, Dominic A. ; Pommier, Yves G. ; Munroe, David J. ; Feinberg, Andrew P ; Weinstein, John N. / Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells. In: Molecular Cancer Therapeutics. 2007 ; Vol. 6, No. 2. pp. 391-403.
@article{e3d605e4024d491a82817a86c9a4c34a,
title = "Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells",
abstract = "E-cadherin (E-cad) is a adhesion glycoprotein, the expression of which is often reduced in invasive or metastatic tumors. To assess E-cad's distribution among different types of cancer cells, we used bisulfitesequencing for detailed, base-by-base measurement of CpG methylation in E-cad's promoter region in the NCI-60 cell lines. The mean methylation levels of the cell lines were distributed bimodally, with values pushed toward either the high or low end of the methylation scale. The 38 epithelial cell lines showed substantially lower (28{\%}) mean methylation levels compared with the nonepithelial cell lines (58{\%}). The CpG site at -143 with respect to the transcriptional start was commonly methylated at intermediate levels, even in cell lines with low overall DNA methylation. We also profiled the NCI-60 cell lines using Affymetrix U133 microarrays and found E-cad expression to be correlated with E-cad methylation at highly statistically significant levels. Above a threshold of ∼ 20{\%} to 30{\%} mean methylation, the expression of E-cad was effectively silenced. Overall, this study provides a type of detailed analysis of methylation that can also be applied to other cancer-related genes. As has been shown in recent years, DNA methylation status can serve as a biomarker for use in choosing therapy.",
author = "Reinhold, {William C.} and Reimers, {Mark A.} and Maunakea, {Alika K.} and Sohyoung Kim and Samir Lababidi and Uwe Scherf and Shankavaram, {Uma T.} and Ziegler, {Micah S.} and Claudia Stewart and Hosein Kouros-Mehr and Hengmi Cui and Douglas Dolginow and Scudiero, {Dominic A.} and Pommier, {Yves G.} and Munroe, {David J.} and Feinberg, {Andrew P} and Weinstein, {John N.}",
year = "2007",
month = "2",
doi = "10.1158/1535-7163.MCT-06-0609",
language = "English (US)",
volume = "6",
pages = "391--403",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells

AU - Reinhold, William C.

AU - Reimers, Mark A.

AU - Maunakea, Alika K.

AU - Kim, Sohyoung

AU - Lababidi, Samir

AU - Scherf, Uwe

AU - Shankavaram, Uma T.

AU - Ziegler, Micah S.

AU - Stewart, Claudia

AU - Kouros-Mehr, Hosein

AU - Cui, Hengmi

AU - Dolginow, Douglas

AU - Scudiero, Dominic A.

AU - Pommier, Yves G.

AU - Munroe, David J.

AU - Feinberg, Andrew P

AU - Weinstein, John N.

PY - 2007/2

Y1 - 2007/2

N2 - E-cadherin (E-cad) is a adhesion glycoprotein, the expression of which is often reduced in invasive or metastatic tumors. To assess E-cad's distribution among different types of cancer cells, we used bisulfitesequencing for detailed, base-by-base measurement of CpG methylation in E-cad's promoter region in the NCI-60 cell lines. The mean methylation levels of the cell lines were distributed bimodally, with values pushed toward either the high or low end of the methylation scale. The 38 epithelial cell lines showed substantially lower (28%) mean methylation levels compared with the nonepithelial cell lines (58%). The CpG site at -143 with respect to the transcriptional start was commonly methylated at intermediate levels, even in cell lines with low overall DNA methylation. We also profiled the NCI-60 cell lines using Affymetrix U133 microarrays and found E-cad expression to be correlated with E-cad methylation at highly statistically significant levels. Above a threshold of ∼ 20% to 30% mean methylation, the expression of E-cad was effectively silenced. Overall, this study provides a type of detailed analysis of methylation that can also be applied to other cancer-related genes. As has been shown in recent years, DNA methylation status can serve as a biomarker for use in choosing therapy.

AB - E-cadherin (E-cad) is a adhesion glycoprotein, the expression of which is often reduced in invasive or metastatic tumors. To assess E-cad's distribution among different types of cancer cells, we used bisulfitesequencing for detailed, base-by-base measurement of CpG methylation in E-cad's promoter region in the NCI-60 cell lines. The mean methylation levels of the cell lines were distributed bimodally, with values pushed toward either the high or low end of the methylation scale. The 38 epithelial cell lines showed substantially lower (28%) mean methylation levels compared with the nonepithelial cell lines (58%). The CpG site at -143 with respect to the transcriptional start was commonly methylated at intermediate levels, even in cell lines with low overall DNA methylation. We also profiled the NCI-60 cell lines using Affymetrix U133 microarrays and found E-cad expression to be correlated with E-cad methylation at highly statistically significant levels. Above a threshold of ∼ 20% to 30% mean methylation, the expression of E-cad was effectively silenced. Overall, this study provides a type of detailed analysis of methylation that can also be applied to other cancer-related genes. As has been shown in recent years, DNA methylation status can serve as a biomarker for use in choosing therapy.

UR - http://www.scopus.com/inward/record.url?scp=33847405772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847405772&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-06-0609

DO - 10.1158/1535-7163.MCT-06-0609

M3 - Article

C2 - 17272646

AN - SCOPUS:33847405772

VL - 6

SP - 391

EP - 403

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 2

ER -